Dose and course of treatment Combined medication Case/control Cancer type Indications and symptoms Efficacy Positive control Side effect Reference 1 1,000–1,500 mg + GS 500 mL, i.v., q.d., 30–45 days No 68/37 Gastric cancer Fever, pain, GI reactions, ascites Relief MMC + UFT Abdominal distention, constipation [11 ] 2 1,000–1,500 mg + GS 500 mL, i.v., q.d., 30 days, total dose of 30–45 g No 44 Hepatocarcinoma Evaluation of curative effect, immune effect, toxic effect Effective treatment, reduction in tumor size, improvement in symptoms and signs, improvement in immune function No Nausea [14 ] 3 30 mL + GS 250 mL, i.v., q.d., 10 days Hydroxycamptothecin 20/20 Hepatocellular carcinoma Recurrence rate HCPT and CKI postoperative arterial infusion may be helpful for reducing intrahepatic recurrence after curative resection for HCC PDD and 5-FU No [15 ] 4 1,000 mg + GS 500 mL, i.v., q.d., 30 days
Carboplatin or 5-FU 21 Malignant ascites Evaluation of curative effect (ascites) Lessening of ascites
Carboplatin or 5-FU Abdominal distention [16 ] 5
50 mL intrapleural injection or 100 mL peritoneal injection, b.i.w., 3 weeks Dexamethasone 24 Virulent succus inside the thorax and belly: lung cancer, breast cancer, ovarian cancer Ascites Lessening of ascites, effective rate (CR and PR) 68.8% No Mild abdominal pain [17 ] 6 1,000 mg + GS 500 mL, i.v., q.d., 30 days, 2–4 cycles MVP/FAM/CAF/FP 65/61 Malignant tumor: lung, esophageal, liver, gastric, breast, colon, nasopharyngeal Toxic effect, QoL Improvement in QoL, reduce the toxic effects (leukopenia, GI reactions) of chemotherapy MVP/FAM/CAF/FP No [18 ] 7 12–15 mL + NS 250 mL, i.v., q.d., 10 days No 52/52 Malignant tumor: lung, breast, gastric, esophageal, colorectal, pancreatic Pain Pain relief Sustained-release indomethacin or tramadol hydrochloride No [19 ] 8 15 mL + NaCl 250 mL, i.v., q.d., for 12 days Fentanyl 31/31 Advanced cancer: gastric, esophageal, breast Pain Pain relief and KPS better than fentanyl,
𝑃
<
0
.
0
5
Fentanyl alone No [20 ] 9 20 mL + NaCl 250 mL, i.v., q.d., for 14 days, 3 cycles Oxaliplatin and capecitabine 36/30 Advanced gastric cancer in senile subjects KPS; toxic effect KPS better than oxaliplatin and capecitabine,
𝑃
<
0
.
0
5
; CKI has a low incidence rate for leukopenia, pain and hepatotoxicity,
𝑃
<
0
.
0
5
Oxaliplatin and capecitabine No [21 ] 10 20 mL, i.v., q.d., 10–14 days Chemotherapy: CAVP or CAP 61/60 Lung cancer Immune Improvement in immune function Chemotherapy: CAVP or CAP No [22 ] 11 30 mL + NaCl 250 mL, i.v., q.d., 7 days Taxol and epirubicin 34/34 Breast cancer Immune Improvement in immune function Taxol and epirubicin No [23 ] 12 20 mL + GS/NaCl 250 mL, i.v., q.d., 14 days, 2 cycles TACE (5-FU 1,000–2,000 mg, MMC 10–20 mg, EP I60–100 mg) 27/23 Liver cancer KPS; toxic effect KPS better than TACE,
𝑃
<
0
.
0
5
; The incidence rate of nausea and vomiting hepatotoxicity were significantly lower than for TACE chemotherapy,
𝑃
<
0
.
0
5
TACE No [24 ] 13 30 mL + GS/NaCl 250 mL, i.v., q.d., 10 days, 4 cycles FOLRIRI chemotherapy 50/50 Advanced colorectal cancer Pain, toxic effect, KPS Pain relief, reduced toxic effect (leukopenia, GI reactions, hepatotoxicity and renal toxicity) of FOLFIRI chemotherapy; improved QoL FOLRIRI chemotherapy No [25 ] 14 20 mL, i.v., q.d., 14 days, 3 cycles Radiotherapy 33/33 Cervical cancer Evaluation of curative effect, KPS, immune toxic effect Improve therapeutic effects, QoL, immune function; attenuate myelosuppression Radiotherapy alone No [26 ] 15 10 mL + NaCl 250 mL i.v. q.d. 10 days DA/TA/MA chemotherapy 35/35 AML KPS, hematotoxicity Improve QoL; attenuate hematotoxicity (leukopenia) of chemotherapy DA/TA/MA chemotherapy No [27 ] 16 20 mL intrapleural injection; keep 48 h q2W and 20 mL + 100 mL NaCl, i.v., q.d., 4 weeks No 32/32 Malignant pleural effusion KPS, evaluation of curative effect, toxic effect Improve QoL and therapeutic effects; reduce toxic effects Cisplatin No [28 ] 17 100 mL, i.v. b.i.d., 10 days Gastric cancer: TPF chemotherapy; colorectal cancer: FOLFOX or FOLFRI chemotherapy; breast cancer: TA or CAF chemotherapy; lung cancer: GP/TP/NP chemotherapy 83/83 Malignant tumors: gastric, lung, colorectal, breast Hepatotoxicity CKI can effectively prevent hepatic injury caused by chemotherapy (incidence and degree of hepatic injuries) Chemotherapy: gastric cancer: TPF; colorectal cancer FOLFOX or FOLFRI; breast cancer: TA or CAF; lung cancer GP/TP/NP No [29 ] 18 20 mL + NaCl 250 mL, i.v., q.d., 21 days, 2 cycles FOLFOX4 chemotherapy 27/21 Gastric cancer Toxic effect Incidence rate of alopecia lower than for FOLFOX4 chemotherapy,
𝑃
<
0
.
0
5
. FOLFOX4 chemotherapy No [30 ] 19 20 mL + NaCl 200 mL, i.v., q.d., 14 days, 2 cycles FOLFX chemotherapy 30/30 Gastric cancer Toxic effect, QoL, symptoms Promote reduction of symptoms, reduce chemotherapy side effects (alopecia, leukopenia, thrombocytopenia, GI reactions), improve QoL and prolong median survival time FOLFX chemotherapy No [31 ] 20 20 mL in NaCl 250 mL, i.v., q.d., for 3-4 weeks, 2-3 cycles Chemotherapy and radiotherapy 75/75 Mid-late-stage cancer: lung, breast, esophageal, nasopharyngeal, colorectal, pancreatic, ovarian Immune, CBR, KPS, toxic effect Improvement in immune function, increase the CBR and QoL and reduce adverse reactions of chemotherapy in patients with midlate-stage cancer. Chemotherapy and radiotherapy (lung cancer: NP/GP/TP + radiotherapy; breast cancer: CAF/TA + radiotherapy: esophageal cancer: PF + radiotherapy; nasopharyngeal carcinoma: DDP + radiotherapy; colorectal cancer: oxaliplatin + 5FU + CF/oxaliplatin + xeloda; pancreatic cancer: GP; ovarian cancer: CAP/TP) No [32 ]
